Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 139
- Registration Number
- NCT03800836
- Locations
- 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇦🇺St Vincents Hospital; Cardiopulmonary transplant Ambulatory Care Dept, Darlinghurst, New South Wales, Australia
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
- Conditions
- Urothelial CarcinomaNon-Small Cell Lung CancerSmall Cell Lung CancerHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2756
- Registration Number
- NCT03782207
- Locations
- 🇧🇬
Multiprofile Hospital for Active Treatment Uni Hospital, Panagyurishte, Bulgaria
🇧🇬Umhat Dr Georgi Stranski, Pleven, Bulgaria
🇧🇬University Hospital Palmed, Plovdiv, Bulgaria
A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 26
- Registration Number
- NCT03779334
- Locations
- 🇦🇺
Sydney Children's Hospital, Randwick, New South Wales, Australia
🇧🇷Hospital das Clinicas - FMUSP_X, Sao Paulo, São Paulo, Brazil
🇵🇱Szpital Gdanskiego Uniwersytetu Medycznego, Gda?sk, Poland
A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RO7017773 in Healthy Participants
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 14
- Registration Number
- NCT03774576
- Locations
- 🇫🇷
BIOTRIAL, Rennes, France
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT03768063
- Locations
- 🇩🇪
Universitaets-Hautklinik Tuebingen, Tübingen, Germany
🇩🇪Universitaettsklinikum Tübingen, Tübingen, Germany
🇩🇪Universitätsklinik Tübingen, Tübingen, Germany
A Study Investigating the Absolute Oral Bioavailability of Balovaptan After Single and Multiple Daily Oral Doses of Balovaptan in Healthy Volunteers
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT03764449
- Locations
- 🇳🇱
Pra International Group B.V, Groningen, Netherlands
A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 55
- Registration Number
- NCT03762681
- Locations
- 🇵🇱
ID Clinic, Myslowice, Poland
🇰🇷Asan Medical Center., Seoul, Korea, Republic of
🇭🇰Queen Mary Hospital, Hong Kong, Hong Kong
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 899
- Registration Number
- NCT03761849
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇵🇱Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii K, Krakow, Poland
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 438
- Registration Number
- NCT03735121
- Locations
- 🇹🇭
Chulalongkorn Hospital, Bangkok, Thailand
🇹🇭Rajavithi Hospital, Bangkok, Thailand
🇦🇷Consultorio Dr. Miguel Angel Escudero, Salta, Argentina
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 454
- Registration Number
- NCT03726879
- Locations
- 🇺🇸
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇺🇸HCA Midwest Division, Kansas City, Missouri, United States
🇺🇸New York University Medical Center PRIME; NYU Langone Medical Center, New York, New York, United States